

1 **Viral infectivity in pediatric SARS-CoV-2 clinical samples does not vary by age**

2 Madaline M. Schmidt¹, Hannah W. Despres¹, David J. Shirley², Michael E. Bose³, Kate C.
3 McCaul³, Jessica W. Crothers⁴, Kelly J. Henrickson³, Benjamin Lee⁵, Emily A. Bruce^{1,*}

4
5 **Affiliations:**

6 ¹Department of Microbiology and Molecular Genetics, Robert Larner, M.D. College of
7 Medicine, University of Vermont, Burlington VT, 05405, USA.

8 ²Faraday, Inc. Data Science Department. Burlington VT, 05405, USA.

9 ³Department of Pediatrics, Medical College of Wisconsin, Milwaukee WI, 53226, USA.

10

11 ⁴Department of Pathology and Laboratory Medicine, Robert Larner, M.D. College of Medicine,
12 University of Vermont, Burlington VT, 05405, USA.

13 ⁵Department of Pediatrics, Robert Larner, M.D. College of Medicine, University of Vermont,
14 Burlington VT, 05405, USA.

15 ***Address correspondence to:** Dr. Emily Bruce, Department of Microbiology and Molecular
16 Genetics, University of Vermont, Burlington VT, 05405, [Emily.bruce@med.uvm.edu]

17 **Short title:** Viral infectivity of pediatric SARS-CoV-2 samples

18 **Conflict of Interest Disclosures:** The authors have no conflicts to disclose.

19 **Funding/Support:** This study was supported by NIH grant P30GM118228-04 (to E.A.B.,
20 J.W.C. and B.L.)

21 **Role of Funder:** The NIH had no role in the design and conduct of the study.

22 **Abbreviations:** SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), COVID-19
23 (coronavirus disease 2019), C_T (cycle threshold), RT-qPCR (reverse transcription-quantitative
24 polymerase chain reaction), RNA (ribonucleic acid), TMPRSS2 (transmembrane protease, serine
25 2), FFU (focus forming unit)

26

27 **Contributors Statement Page**

28 Madaline Schmidt collected data, carried out the initial analyses, drafted the initial manuscript
29 and critically reviewed and revised the manuscript.

30

31 Hannah Despres collected data and critically reviewed and revised the manuscript.

32

33 David Shirley carried out data analysis and presentation, and critically reviewed and revised the
34 manuscript.

35

36 Michael Bose and Kate McCaul coordinated sample collection and acquisition, and critically
37 reviewed and revised the manuscript.

38

39 Dr Jessica Crothers conceptualized and designed the study and critically reviewed and revised
40 the manuscript.

41

42 Dr Kelly Henrickson conceptualized and designed the study, coordinated sample collection and
43 IRB permission (MCW), and critically reviewed and revised the manuscript.

44

45 Dr Benjamin Lee conceptualized and designed the study, coordinated sample acquisition and
46 IRB permission (UVM), and critically reviewed and revised the manuscript.

47

48 Dr Emily Bruce conceptualized and designed the study, coordinated and supervised data
49 collection, drafted the initial manuscript and critically reviewed and revised the manuscript.

50

51 All authors approved the final manuscript as submitted and agree to be accountable for all
52 aspects of the work.

53

54

55

56

57

58

59

60

61

62

63 INTRODUCTION

64 During the early months of the SARS-CoV-2 pandemic, notable uncertainty emerged regarding
65 the role of children in transmission dynamics ¹. With time, it became more clear that children
66 were susceptible to infection with SARS-CoV-2, but that the vast majority of children
67 experienced mild symptoms with lower incidence of severe disease ². This pattern remained
68 consistent despite the later emergence of SARS-CoV-2 variants, including Delta and Omicron,
69 even among children <5 ineligible for vaccination³. The relative lack of severe disease in the
70 pediatric population raised questions regarding viral kinetics and infectivity in children versus
71 adults.

72 We hypothesized that unique virologic features in children could explain this apparent
73 decrease in symptoms and transmissibility early in the pandemic. Due to the challenges posed by
74 measurement of infectious viral titers, the majority of work examining viral loads in clinical
75 samples has measured viral RNA levels, as determined by RT-qPCR cycle threshold [C_T]. A
76 previous study using this technique reported no differences in viral RNA load in adults and
77 children, when controlling for the presence of symptoms ⁴. A different study reported both RNA
78 viral load and level of infectious virus using a semi-quantitative method (TCID₅₀) in pediatric
79 clinical samples ⁵. In contrast however, other work indicates that ancestral SARS-CoV-2
80 replicates less efficiently in both children and pediatric versus adult nasal epithelial cells, a
81 defect that Omicron was able to abolish ⁵⁻⁷. Finally, we and others have demonstrated a dynamic
82 relationship between C_T values and infectious viral titers with potential for significant
83 discrepancies and a ratio dependent on both viral and host factors, ⁸ but this work did not include
84 children ⁹.

85 Therefore, to further understand SARS-CoV-2 infection in children, we investigated the
86 ratio of infectious virus titer to RNA viral load in children aged 0 to <18 years old. We
87 hypothesized that the ratio of infectious virus to RNA viral load would be positively associated
88 with age.

89

90 METHODS

91 **Sample Selection**

92 Banked SARS-CoV-2 positive nasopharyngeal specimens from children 0 to <18 years old
93 collected and stored at Children’s Wisconsin, Milwaukee, Wisconsin between September 14,
94 2020 and May 17, 2021 were identified. Deidentified samples were binned into four age groups
95 (<1, 1-5, 6-11, and 12-17) and stratified by clinical C_T value (<20, 20-24, 25-29, and 30-34) to
96 select a sample of children representing the full spectrum of both age and C_T value . The study
97 received an exempt determination for use of deidentified specimens from the University of
98 Vermont (UVM) Institutional Review Board and the Children’s Wisconsin Institutional Review
99 Board.

100

101 **RNA extractions and RT-PCR**

102 Total nucleic acid was extracted on the NucliSENS easyMAG or EMAG automated extraction
103 instruments (bioMerieux). SARS-CoV-2 RNA was detected using previously published
104 primers/probes for the SARS-CoV-2 E gene (Sarbeco¹⁰) on the 7500 Fast Real-Time PCR
105 System or QuantStudio 7 Pro platforms.

106

107 **Viral Titrations**

108 SARS-CoV-2 viral titering was conducted under BSL-3 conditions at UVM using a microfocus
109 forming unit (FFU) assay in VeroE6-TMPRSS2 cells, which increases assay sensitivity
110 compared to standard VeroE6 cells, as previously described ⁸.

111

112 **Statistical Analysis**

113 Viral titers were log-transformed for analysis. Linear regression was used to predict log titer as a
114 function of C_T , fitting separate models without age and to control for continuous and categorical
115 age effects. Models were compared by F test. Data were analyzed and plotted with R. Code is
116 available at <https://github.com/emilybrucelab>.

117

118 **RESULTS**

119 N=144 clinical specimens were selected to determine the relationship between the
120 infectivity of SARS-CoV-2 in pediatric samples and RNA viral load. As expected, higher RNA
121 viral load generally correlated with higher infectious virus titer, although as reported previously
122 this ratio was somewhat variable ^{8,9}. In linear regression, the relationship between infectious viral
123 titer and C_T was not significantly modified by age ($P=0.156$) or age group ($P=0.355$ overall by F
124 test). These data indicate that there is no difference in the infectiousness of SARS-CoV-2
125 produced by children, regardless of age.

126

127 **DISCUSSION**

128 Consistent with previous findings, we found no significant differences in the relationship
129 between SARS-CoV-2 infectious virus titer and RNA viral load in children across the pediatric
130 age spectrum ^{4,7}. Our findings suggest equal levels of viral infectivity in children and in adults

131 with similar RNA viral loads. Limitations of this study include lack of access to viral
132 sequencing and individual level metadata, which could reveal differences in infectivity as a result
133 of viral genetic background, days post-symptom onset, host immune status, and vaccination
134 status. Furthermore, there was no direct comparison with adult samples, although we did include
135 samples in older teens who would closely resemble adults biologically.

136

137 ACKNOWLEDGEMENTS


138 We thank Ms. Kubinski and Dr. Oetjen for technical assistance.

139

140 REFERENCES

- 141 1. Lee B, Raszka WV, Jr. COVID-19 Transmission and Children: The Child Is Not to
142 Blame. *Pediatrics*. 2020;146(2).
- 143 2. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. *New England Journal of*
144 *Medicine*. 2020;382(17):1663-1665.
- 145 3. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Incidence Rates and
146 Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in
147 Children Younger Than 5 Years in the US. *JAMA Pediatrics*. 2022;176(8):811-813.
- 148 4. Chung E, Chow EJ, Wilcox NC, et al. Comparison of Symptoms and RNA Levels in
149 Children and Adults With SARS-CoV-2 Infection in the Community Setting. *JAMA*
150 *Pediatrics*. 2021;175(10):e212025-e212025.
- 151 5. Yonker LM, Boucau J, Regan J, et al. Virologic Features of Severe Acute Respiratory
152 Syndrome Coronavirus 2 Infection in Children. *J Infect Dis*. 2021;224(11):1821-1829.
- 153 6. Jones TC, Biele G, Mühlemann B, et al. Estimating infectiousness throughout SARS-
154 CoV-2 infection course. *Science*. 2021;373(6551).
- 155 7. Zhu Y, Chew KY, Wu M, et al. Ancestral SARS-CoV-2, but not Omicron, replicates less
156 efficiently in primary pediatric nasal epithelial cells. *PLOS Biology*.
157 2022;20(8):e3001728.
- 158 8. Despres HW, Mills MG, Shirley DJ, et al. Measuring infectious SARS-CoV-2 in clinical
159 samples reveals a higher viral titer:RNA ratio for Delta and Epsilon vs. Alpha variants.
160 *Proc Natl Acad Sci U S A*. 2022;119(5).
- 161 9. Puhach O, Adea K, Hulo N, et al. Infectious viral load in unvaccinated and vaccinated
162 patients infected with SARS-CoV-2 WT, Delta and Omicron. *medRxiv*.
163 2022:2022.2001.2010.22269010.
- 164 10. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-
165 nCoV) by real-time RT-PCR. *Euro Surveill*. 2020;25 (3).

166



167

168 **Figure 1. SARS-CoV-2 viral infectivity does not vary by age in a pediatric population.**

169 A set of 144 clinical samples from children infected with SARS-CoV-2 was used to examine the
170 relationship between infectious virus titer and RNA viral load as a function of patient age.

171 Individual specimen measurements of E gene RNA levels (C_T) on the x-axis are plotted against
172 viral titer, as measured in focus forming units (FFU/mL) on the y-axis. Dashed line indicates the
173 limit of detection for infectious titer (20 FFU/mL). Samples for which we could not measure a
174 viral titer were assigned fixed values of one-tenth the limit of detection (2 FFU/mL). Lines of
175 best fit were generated by linear regression on log-transformed titer data as a function of C_T and
176 age group.

177

178

179

180

181

182